Stereotactic body radiotherapy for localized prostate cancer: Disease control and quality of life at 6 years

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Katz, Alan J ^a   Santoro, Michael ^a   Diblasio, Fred ^b   Ashley, Richard ^c  

^a Flushing Radiation Oncology   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c North Shore LIJ System ^*  (United States)

Author keywords

CyberKnife; Prostate; Stereotactic body radiotherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; DISEASE CONTROL; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE; RECTUM DISEASE; SEXUAL DYSFUNCTION; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT OUTCOME; URINARY TRACT DISEASE; ADENOCARCINOMA; ADJUVANT THERAPY; ADVERSE EFFECTS; BLOOD; COMPUTER ASSISTED RADIOTHERAPY; FIDUCIAL MARKER; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; RADIOSURGERY; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; FIDUCIAL MARKERS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOSURGERY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;

EID: 84877613382     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-118     Document Type: Article

References (34)

1. Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS, Eley JW, Stephenson RA, Harlan LC. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the prostate cancer outcomes study. J Natl Cancer Inst 2000, 92:1582-1592. 10.1093/jnci/92.19.1582, 11018094.
2. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008, 358:1250-1261. 10.1056/NEJMoa074311, 18354103.
3. Robinson JW, Moritz S, Fung T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys 2002, 54:1063-1068. 10.1016/S0360-3016(02)03030-4, 12419432.
4. Siglin J, Kubicek GJ, Leiby B, Valicenti RK. Time of decline in sexual function after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010, 76:31-35. 10.1016/j.ijrobp.2009.01.070, 19395191.
5. Force USPST. Screening for prostate cancer: U.S. Preventive services task force recommendation statement. Ann Intern Med 2008, 149:185-191.
6. Dasu A, Toma-Dasu I. Prostate alpha/beta revisited - an analysis of clinical results from 14 168 patients. Acta Oncol 2012, 51:963-974. 10.3109/0284186X.2012.719635, 22966812.
7. Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys 2012, 82:e17-e24. 10.1016/j.ijrobp.2010.10.075, 21324610.
8. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999, 43:1095-1101. 10.1016/S0360-3016(98)00438-6, 10192361.
9. Collins CD, Lloyd-Davies RW, Swan AV. Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation technique. Clin Oncol (R Coll Radiol) 1991, 3:127-132.
10. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: cleveland clinic experience. Int J Radiat Oncol Biol Phys 2007, 68:1424-1430. 10.1016/j.ijrobp.2007.01.067, 17544601.
11. Livsey JE, Cowan RA, Wylie JP, Swindell R, Read G, Khoo VS, Logue JP. Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis. Int J Radiat Oncol Biol Phys 2003, 57:1254-1259. 10.1016/S0360-3016(03)00752-1, 14630259.
12. Lukka H, Hayter C, Julian JA, Warde P, Morris WJ, Gospodarowicz M, Levine M, Sathya J, Choo R, Prichard H. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005, 23:6132-6138. 10.1200/JCO.2005.06.153, 16135479.
13. Yeoh EE, Holloway RH, Fraser RJ, Botten RJ, Di Matteo AC, Butters J, Weerasinghe S, Abeysinghe P. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 2006, 66:1072-1083. 10.1016/j.ijrobp.2006.06.005, 16965866.
14. Demanes DJ, Martinez AA, Ghilezan M, Hill DR, Schour L, Brandt D, Gustafson G. High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2011, 81:1286-1292. 10.1016/j.ijrobp.2010.10.015, 21310546.
15. Demanes DJ, Rodriguez RR, Schour L, Brandt D, Altieri G. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys 2005, 61:1306-1316. 10.1016/j.ijrobp.2004.08.014, 15817332.
16. Martinez A, Gonzalez J, Spencer W, Gustafson G, Kestin L, Kearney D, Vicini FA. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urol 2003, 169:974-979. discussion 979-980, 10.1097/01.ju.0000052720.62999.a9, 12576825.
17. Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007, 67:1099-1105. 10.1016/j.ijrobp.2006.10.050, 17336216.
18. King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 2009, 73:1043-1048. 10.1016/j.ijrobp.2008.05.059, 18755555.
19. Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol 2010, 10:1. 10.1186/1471-2490-10-1, 2831888, 20122161.
20. Aluwini S, van Rooij P, Hoogeman M, Bangma C, Kirkels WJ, Incrocci L, Kolkman-Deurloo IK. CyberKnife stereotactic radiotherapy as monotherapy for low- to intermediate-stage prostate cancer: early experience, feasibility, and tolerance. J Endourol 2010, 24:865-869. 10.1089/end.2009.0438, 20433370.
21. Bolzicco G, Favretto MS, Scremin E, Tambone C, Tasca A, Guglielmi R. Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: preliminary clinical results. Technol Cancer Res Treat 2010, 9:473-477.
22. Jabbari S, Weinberg VK, Kaprealian T, Hsu IC, Ma L, Chuang C, Descovich M, Shiao S, Shinohara K, Roach M, Gottschalk AR. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int J Radiat Oncol Biol Phys 2012, 82:228-234. 10.1016/j.ijrobp.2010.10.026, 21183287.
23. Kang JK, Cho CK, Choi CW, Yoo S, Kim MS, Yang K, Yoo H, Kim JH, Seo YS, Lee DH, Jo M. Image-guided stereotactic body radiation therapy for localized prostate cancer. Tumori 2011, 97:43-48.
24. McBride SM, Wong DS, Dombrowski JJ, Harkins B, Tapella P, Hanscom HN, Collins SP, Kaplan ID. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: Preliminary results of a multi-institutional phase 1 feasibility trial. Cancer 2012, 118:3681-3690. 10.1002/cncr.26699, 22170628.
25. Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol 2011, 6:3. 10.1186/1748-717X-6-3, 3022740, 21219625.
26. Romanelli P, Schaal DW, Adler JR. Image-guided radiosurgical ablation of intra- and extra-cranial lesions. Technol Cancer Res Treat 2006, 5:421-428.
27. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000, 56:899-905. 10.1016/S0090-4295(00)00858-X, 11113727.
28. Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference. Int J Radiat Oncol Biol Phys 2006, 65:965-974. 10.1016/j.ijrobp.2006.04.029, 16798415.
29. Ray ME, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Shipley WU, Zelefsky MJ. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys 2006, 64:1140-1150. 10.1016/j.ijrobp.2005.07.006, 16198506.
30. Stock RG, Klein TJ, Cesaretti JA, Stone NN. Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy. Int J Radiat Oncol Biol Phys 2009, 74:753-758. 10.1016/j.ijrobp.2008.08.049, 19084351.
31. Katz AJ, Santoro M, Ashley R, Diblasio F. Stereotactic body radiation therapy for low- and low-intermediate-risk prostate cancer: is there a dose effect?. Front Rad Oncol 2011, 1:49.
32. Katz A, Freeman D, Aronovitz J, Fuller D, Bolzicco G, Meier R, Collins S, Wang J, Steinberg M, King CR. Five-year biochemical control rates for stereotactic body radiation therapy for organ-confined prostate cancer: A multi-institutional pooled analysis 2012, Boston, MA: American Society of Radiation Oncology.
33. Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M. Stereotactic body radiotherapy as boost for organ-confined prostate cancer. Technol Cancer Res Treat 2010, 9:575-582.
34. Katz A, Ferrer M, Suarez JF. Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer. Radiat Oncol 2012, 7:194. 10.1186/1748-717X-7-194, 3528663, 23164305.